3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
6
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Neoplasms
7
Multiple Myeloma
7
Lymphoma
7
Carcinoma, Non-Small-Cell Lung
6
Lymphoma, T-Cell, Cutaneous
4
Mycosis Fungoides
3
Sezary Syndrome
2
Recurrence
2
Lymphoproliferative Disorders
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Vascular Diseases
1
Stage IIIB or IV Non-Small Cell Lung Cancer
1
Paraproteinemias
1
Pancreatic Neoplasms
1
Neuroectodermal Tumors
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Myelodysplastic Syndromes
1
Mesothelioma
1
Melanoma
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell
1
Lymphatic Diseases
1
Lung Neoplasms
1
Leukemia
1
Interventions
Carboplatin
98
Pemetrexed
70
pembrolizumab
68
Cisplatin
59
Paclitaxel
54
Docetaxel
45
Gemcitabine
37
Erlotinib Hydrochloride
24
Nivolumab
23
osimertinib
17
Bevacizumab
17
durvalumab
14
Cetuximab
13
130-nm albumin-bound paclitaxel
13
Gefitinib
11
Etoposide
11
Drug Therapy
11
Ipilimumab
9
Injections
9
Albumin-Bound Paclitaxel
9
Vinorelbine
8
Radiotherapy
8
motexafin gadolinium
7
capmatinib
7
atezolizumab
7
epacadostat
6
Taxes
6
Cyclophosphamide
6
vandetanib
5
entinostat
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lung Neoplasms
×
Vorinostat
×
Clear all
NCT00128102
2020-10-26
MK-0683-014
Merck Sharp & Dohme LLC
Phase 3
Completed
661 enrolled
18 charts